DeutschNewstral
Yaron Werber
Vivek Ramaswamy’s Poll Numbers Are Down. So Is His Net Worth.Forbes- BThe FDA Rejects FibroGen Drug. The Damage to the Stock Is Already Done.2 min readbarrons.com
- BFibroGen Stock Falls Following Disclosure of a "Major 'Oops'"barrons.com
- BIonis Stock Plunges as Monitoring Board Halts Huntington's Disease Trialbarrons.com
- BWall Street Looks Again at Bluebird, Rivals, After Gene-Therapy Setbackbarrons.com
- BAstraZeneca Launched a 30,000-Person Trial of Covid-19 Vaccine. Where Things Stand.barrons.com
- BRegeneron Signs Up Roche to Help Manufacture Covid-19 Antibodybarrons.com
- BRegeneron Pharmaceuticals Reports Earnings Tomorrow. Here’s What to Expect.barrons.com
- BRegeneron Jumps After Earnings Beat Expectationsbarrons.com
- BA Few Good Stocks, Some Wild Economic Predictionsbarrons.com
- BCoronavirus Outbreak Could Disrupt Drug Companies’ Clinical Trialsbarrons.com
- BAcceleron Stock Is Skyrocketing After Surprise Drug-Trial Successbarrons.com
- BAcceleron Gives Up on Rare Genetic Disease. Analysts Are Still Bullish on the Stock.barrons.com
- BAmgen’s Court Win Could Mark ‘a New Dawn’ for the Stockbarrons.com
- BUnum Therapeutics Dives After Cancer Drug Trial Suspendedbarrons.com
- BBluebird Bio's Gene Therapy Is $1.8 Million Per Patient. The Stock Is Falling.barrons.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.